Search clinical trials for: HIV-1 GW873140 CCR5 antagonist treatment experienced

Total 130653 results

University of Cincinnati
University of California, San Francisco; Case Western Reserve University

Completed

CCR5-modified CD4+ T Cells for HIV Infection (TRAILBLAZER)

HIV Infections

United States
Imperial College London
Pfizer

Completed

The Maraviroc Central Nervous System (CNS) Study

HIV Infections

United Kingdom
Rockefeller University
Pfizer; Aaron Diamond AIDS Research Center

Completed

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

HIV Infections

United States
City of Hope Medical Center
Sangamo Therapeutics; California Institute for Regenerative Medicine (CIRM)

Active, not recruiting

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

HIV

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

HIV-1 | Anti-Retroviral Agents
ViiV Healthcare
Pfizer

Completed

Multicenter, Safety Study Of Maraviroc

Acquired Immunodeficiency Syndrome | HIV Infection

Brazil
University of Nairobi
ViiV Healthcare

Completed

Second-line Switch to Dolutegravir Study (2SD)

HIV-1-infection

Kenya
University Hospital, Strasbourg, France

Unknown

Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients (DRONE)

HIV-1 Infection

France
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

HIV Infections | HIV-1 Infection
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Biocine

Completed

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

HIV Infections | HIV Seronegativity

United States, Puerto Rico
Tulika Singh, MD
Gilead Sciences

Recruiting

Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age

HIV-1-infection

United States
AbbVie

Completed

The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation (SIMPLE)

HIV-1 Infection
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

HIV-1 Infection

United States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
Instituto Nacional de Ciencias Medicas y Nutricion...
University of Pennsylvania; University of Witwatersrand, South Africa; Case Western... and other collaborators

Unknown

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients (CADIRIS)

HIV Infections | HIV | Immune Reconstitution Inflammatory Syndrome

Mexico, United States, South Africa
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
CytoDyn, Inc.

Active, not recruiting

PRO 140 in Treatment-Experienced HIV-1 Subjects

HIV-1-infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

HIV-1 Infection

United States, Puerto Rico
Asociación Civil Impacta Salud y Educación, Peru
amfAR, The Foundation for AIDS Research; The Fenway Institute; Epicentro

Completed

Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade

HIV-1-infection

Peru
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

HIV-1 Infection

United States, Peru, Puerto Rico, Brazil, Botswana, Kenya, South Africa, Thailand
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

HIV-1 Infection

United States
ViiV Healthcare
Pfizer

Terminated

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

HIV Infections

United States, Canada
Viriom

Completed

Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs

HIV-1-infection

Russian Federation
University of California, San Diego
University of California, Los Angeles; Pfizer; University of Southern California and other collaborators

Completed

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

HIV Infections

United States
Imperial College London
Mater Misericordiae University Hospital

Terminated

The St. Marys and The Mater Switch Study (SMASH)

HIV Infections

Ireland, United Kingdom
University of California, San Francisco
National Heart, Lung, and Blood Institute (NHLBI); Pfizer

Completed

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

HIV Infections | HIV Infection | Inflammation | Cardiovascular Disease

United States
AB Biotics, SA
Germans Trias i Pujol Hospital

Completed

Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic (RECOVER)

HIV | Premature Aging

Spain
VGX Pharmaceuticals, LLC

Completed

Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

HIV Infections

United States, Brazil
Centre Hospitalier Intercommunal de Toulon La Seyne...
Merck Sharp & Dohme LLC; Abbott

Completed

IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients (IntensVIH)

HIV Infections

France
Sangamo Therapeutics

Completed

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

HIV Infections | HIV Infection

United States
Fundación Huésped
Pfizer

Unknown

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients (TERCETO)

AIDS | HIV-1 Adults Patients | Triple Class Failure

Argentina
ASST Fatebenefratelli Sacco

Completed

Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects

HIV Infections

Italy
Temple University
Pfizer; Abbott

Terminated

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) (KALMAR)

HIV Infections

United States
University of Oxford
National Institute of Allergy and Infectious Diseases (NIAID); University of...

Completed

Tambua Mapema Plus - to Discover HIV Infection Early and Prevent Onward Transmission (TMP)

HIV Infections

Kenya
University of Kansas Medical Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Piloting At-birth Point of Care HIV Testing Strategies in Kenya

HIV Infections

United States, Kenya
University of Hawaii
Pfizer

Completed

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

HIV Infections

United States
ViiV Healthcare
Pfizer

Active, not recruiting

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Human Immunodeficiency Virus

Spain, United States, Italy, South Africa, Brazil, Mexico, Portugal, Puerto Rico, Thailand
Affiliated Hospital of Guangdong Medical University

Not yet recruiting

Safety and Efficacy Clinical Study of KL-HIV-Tri01 in the Treatment of HIV Infected Subjects

HIV Infections
Thrasher Research Fund
Centers for Disease Control and Prevention

Completed

Use of OraQuick for Screening HIV in Children Less Than Eighteen Months Old

HIV Antibody Testing

Zambia
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

HIV Infections

United States, Switzerland
Universitair Ziekenhuis Brussel

Terminated

Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals (BONBO)

HIV-1 | Treatment-naïve

Belgium
University of California, San Francisco
Pfizer; Stanford University; amfAR, The Foundation for AIDS Research; Case Western... and other collaborators

Completed

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

HIV Infection

United States
Gilead Sciences

Completed

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

HIV Infections

United Kingdom
Merck Sharp & Dohme LLC

Withdrawn

Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285

HIV Infections | Acquired Immunodeficiency Syndrome
S.F.L. van Lelyveld
Pfizer; Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van... and other collaborators

Completed

Maraviroc Immune Recovery Study (MIRS)

HIV Infections

Netherlands
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France; University... and other collaborators

Completed

Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention (PROMISE-EPI)

HIV-1

Burkina Faso, Zambia
Hospital Universitari Vall d'Hebron Research Institute
Gilead Sciences

Completed

Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla

HIV-1

Spain
Hospital Universitari Vall d'Hebron Research Institute
University Hospital, Ghent; IrsiCaixa

Completed

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

HIV-1

Spain

Search clinical trials for: HIV-1 GW873140 CCR5 antagonist treatment experienced

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations